CD Private Equity Fund III (ASX:CD3 – Get Free Report) declared a interim dividend on Wednesday, January 24th, MarketIndexAU reports. Shareholders of record on Thursday, February 22nd will be paid a dividend of 0.15 per share on Thursday, February 22nd. This represents a yield of 9.74%. The ex-dividend date is Sunday, January 28th. This is […]
CD Private Equity Fund III (ASX:CD3 – Get Free Report) announced a interim dividend on Wednesday, January 24th, MarketIndexAU reports. Investors of record on Thursday, February 22nd will be paid a dividend of 0.15 per share on Thursday, February 22nd. This represents a yield of 9.74%. The ex-dividend date is Sunday, January 28th. This is […]
An international, open-label trial demonstrated the overall survival benefits of administering tebentafusp to HLA-A 02:01-positive patients with metastatic uveal melanoma.
Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.
Scientists at Regeneron Pharmaceuticals Inc. have found a new way to permanently stop allergy through a combination of therapies that prevents the production of antibodies in secondary lymphoid organs and in bone marrow.